EVOKE PHARMA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-11-29: Form 8-K; Period of report 2023-11-27; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-11-27: Form 8-K; Period of report 2023-11-27; Description 8.01 Other Events; Details 8.01.
- 2023-11-22: Form 8-K; Period of report 2023-11-21; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-11-09: Form 8-K; Period of report 2023-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-11-29 | 8-K | 2023-11-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously announced, on November 21, 2023, Evoke Pharma, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, due to the Company’s non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”),which requires listed companies to maintain stockholders’ equity of at least $2.5 million, the Company was subject to delisting unless it timely requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”). | evok-20231127.htm |
| 2023-11-27 | 8-K | 2023-11-27 | 8.01 Other Events | 8.01 On November 27, 2023, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced that the Company’s recently issued patent entitled “Nasal Formulations of Metoclopramide” (U.S. patent No. 11,813,231), which covers GIMOTI nasal spray, has been listed in the U.S. Food and Drug Administration’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book. | evok-20231127.htm |
| 2023-11-22 | 8-K | 2023-11-21 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously announced, on May 24, 2023, Evoke Pharma, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”),which requires listed companies to maintain stockholders’ equity of at least $2.5 million. | evok-20231121.htm |
| 2023-11-09 | 8-K | 2023-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2023, Evoke Pharma, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023. | evok-20231109.htm |
| 2023-11-01 | 8-K | 2023-10-31 | 8.01 Other Events | 8.01 On October 30, 2023, Evoke Pharma, Inc. (the “Company") announced a summary of real-world data on the positive impact of GIMOTI (nasal metoclopramide) usage in reducing healthcare costs for patients suffering from diabetic gastroparesis (DGP) versus patients taking oral metoclopramide. | evok-20231031.htm |
| 2023-10-12 | 8-K | 2023-10-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | evok-20231009.htm |
| 2023-08-10 | 8-K | 2023-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2023, Evoke Pharma, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023. | evok-20230810.htm |
| 2023-07-21 | 8-K | 2023-07-19 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously announced, on May 24, 2023, Evoke Pharma, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the Company’s stockholders’ equity of $2.1 million as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), which requires listed companies to maintain stockholders’ equity of at least $2.5 million. | evok-20230719.htm |
| 2023-05-26 | 8-K | 2023-05-24 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 24, 2023, Evoke Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the Company’s stockholders’ equity of $2.1 million as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5 million. | evok-20230524.htm |
| 2023-05-15 | 8-K | 2023-05-15 | 2.02 Results of Operations and Financial Condition | 2.02 On May 15, 2023, Evoke Pharma, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023. | evok-20230515.htm |
| 2023-05-11 | 8-K | 2023-05-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 Evoke Pharma, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) solely by means of remote communication through a live webcast on May 10, 2023, at 8:30 a.m., Pacific Time. 5.07 The Company held its Annual Meeting solely by means of remote communication through a live webcast on May 10, 2023, at 8:30 a.m., Pacific Time. | evok-20230510.htm |
| 2023-05-09 | 8-K | 2023-05-09 | 8.01 Other Events | 8.01 On May 9, 2023, Evoke Pharma, Inc. (“Evoke” or the “Company”), and EVERSANA, the Company's commercial partner, announced the details of the Company's presentation at Digestive Disease Week 2023 demonstrating that GIMOTI reduces healthcare resource utilization for patients with diabetic gastroparesis versus patients on oral metoclopramide. | evok-20230509.htm |
| 2023-05-01 | 8-K | 2023-05-01 | 8.01 Other Events | 8.01 On May 1, 2023, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced that the Company’s recently issued patent entitled “Nasal Formulations of Metoclopramide” (U.S. patent No. 11,628,150), which covers GIMOTI nasal spray, has been listed in the U.S. Food and Drug Administration’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book. | evok-20230501.htm |
| 2023-04-20 | 8-K | 2023-04-20 | 8.01 Other Events | 8.01 On April 20, 2023, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced that the United States Patent and Trademark Office issued U.S. patent No. 11,628,150 for GIMOTI nasal spray. | evok-20230420.htm |
| 2023-04-06 | 8-K | 2023-04-06 | 8.01 Other Events | 8.01 On April 6, 2023, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI nasal spray. | evok-20230406.htm |
| 2023-03-23 | 8-K | 2023-03-23 | 8.01 Other Events | 8.01 On March 23, 2023, Evoke Pharma, Inc. (the “Company”) and Eversana Life Science Services LLC., the Company’s commercialization partner, presented a summary of real-world data on the positive impact of GIMOTI usage in decreasing the utilization of healthcare resources by patients with diabetic gastroparesis (“DGP”). | evok-20230323.htm |
| 2023-03-21 | 8-K | 2023-03-21 | 2.02 Results of Operations and Financial Condition | 2.02 On March 21, 2023, Evoke Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022. | evok-20230321.htm |
| 2023-02-21 | 8-K | 2023-02-21 | 8.01 Other Events | 8.01 On February 21, 2023, Evoke Pharma, Inc. (the “Company”) and Eversana Life Science Services LLC., the Company’s commercialization partner, announced that the Company’s abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW) 2023. | evok-20230221.htm |
| 2023-02-13 | 8-K | 2023-02-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Arrangements of Certain Officers. | evok-20230208.htm |
| 2023-01-30 | 8-K | 2023-01-30 | 8.01 Other Events | 8.01 On January 30, 2023, Evoke Pharma, Inc. (the “Company”) announced that a joint stipulation of dismissal has been filed in the GIMOTI® (metoclopramide) patent infringement case (Civil Action No. 1:22-cv-02019). | evok-20230130.htm |